Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis - Report - MDSpire
Advertisement
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis
Clinical Report: Outcomes of Ublituximab in Treatment-Naïve Patients
Overview
Ublituximab demonstrated superior efficacy compared to teriflunomide in treatment-naïve patients with relapsing multiple sclerosis, showing lower annualized relapse rates and improved disability outcomes.
Background
The early initiation of high-efficacy disease-modifying therapies (DMTs) is critical in managing relapsing multiple sclerosis (RMS) to reduce disability progression and relapse rates. Ublituximab, a novel anti-CD20 monoclonal antibody, offers a promising option for treatment-naïve patients.
Data Highlights
Outcome
Ublituximab
Teriflunomide
p-value
Annualized Relapse Rate (ARR)
0.081 (n=345)
0.188 (n=377)
<0.001
12-week Confirmed Disability Improvement
10.7%
5.3%
0.010
Gd+ T1 Lesions
0.031
0.791
<0.001
New/Enlarging T2 Lesions
0.390
4.144
<0.001
Key Findings
Ublituximab resulted in a significantly lower annualized relapse rate compared to teriflunomide in treatment-naïve patients (0.081 vs. 0.188, p < 0.001).
In the early treatment subpopulation, ublituximab also showed a lower annualized relapse rate (0.130 vs. 0.334, p = 0.004).
The rate of 12-week confirmed disability improvement was higher with ublituximab than teriflunomide (10.7% vs. 5.3%, p = 0.010).
Ublituximab significantly reduced gadolinium-enhancing T1 lesions compared to teriflunomide (0.031 vs. 0.791, p < 0.001).
New/enlarging T2 lesions were also significantly lower in the ublituximab group (0.390 vs. 4.144, p < 0.001).
Clinical Implications
The findings indicate that ublituximab may be a more effective treatment option for patients with relapsing multiple sclerosis who are treatment-naïve. Early initiation of high-efficacy DMTs like ublituximab could lead to better long-term outcomes in this patient population.
Conclusion
Ublituximab shows significant efficacy in treatment-naïve patients with relapsing multiple sclerosis.
by Derrick Robertson, Enrique Alvarez, Lawrence Steinman, Hans-Peter Hartung, Peiqing Qian, Krzysztof Selmaj, Sibyl Wray, Daniel Wynn, Edward J. Fox, Koby Mok, Hari P. Miskin, Yihuan Xu, Christopher A. Garner, Bruce A. C. Cree
The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.
